US 11,746,371 B2
Methods for treating polymicrobial infections
David A. Baunoch, Irvine, CA (US); Miguel F. R. Penaranda, Irvine, CA (US); Michael L. Opel, Irvine, CA (US); Maher Badir, Irvine, CA (US); and Natalie Luke, Irvine, CA (US)
Assigned to CAP DIAGNOSTICS, LLC, Irvine, CA (US)
Filed by CAP DIAGNOSTICS, LLC, Irvine, CA (US)
Filed on Jun. 1, 2021, as Appl. No. 17/335,767.
Application 17/335,767 is a division of application No. 16/848,651, filed on Apr. 14, 2020, granted, now 11,053,532.
Application 16/848,651 is a continuation in part of application No. 16/216,751, filed on Dec. 11, 2018, abandoned.
Application 16/216,751 is a continuation of application No. 15/957,780, filed on Apr. 19, 2018, granted, now 10,160,991, issued on Dec. 25, 2018.
Claims priority of provisional application 63/009,337, filed on Apr. 13, 2020.
Claims priority of provisional application 62/988,186, filed on Mar. 11, 2020.
Claims priority of provisional application 62/978,149, filed on Feb. 18, 2020.
Claims priority of provisional application 62/977,637, filed on Feb. 17, 2020.
Claims priority of provisional application 62/956,923, filed on Jan. 3, 2020.
Claims priority of provisional application 62/928,815, filed on Oct. 31, 2019.
Claims priority of provisional application 62/924,614, filed on Oct. 22, 2019.
Claims priority of provisional application 62/487,395, filed on Apr. 19, 2017.
Prior Publication US 2021/0301315 A1, Sep. 30, 2021
Int. Cl. C12Q 1/14 (2006.01); C12Q 1/08 (2006.01); G01N 21/59 (2006.01)
CPC C12Q 1/08 (2013.01) [G01N 21/59 (2013.01); G01N 21/5907 (2013.01); G01N 2021/593 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method for treating a patient having or suspected of having a polymicrobial infection comprising a combination of Escherichia coli (E. coli) and coagulase-negative Staphylococcus (CoNS), the method comprising:
a. detecting the presence of both E. coli and CoNS in a source of the infection obtained from the patient; and
b. administering to the patient a therapeutically effective amount of an antibiotic selected from the group consisting of: (i) a combination of amoxicillin and clavulanate; (ii) ceftriaxone; (iii) tetracycline or doxycycline; and (iv) a combination of trimethoprim and sulfamethoxazole; wherein the E. coli and CoNS together have a decreased odds of resistance to one or more of the antibiotics, and wherein the antibiotics are effective for killing or inhibiting growth of the E. coli and CoNS to treat the polymicrobial infection.